AZD-9291 CAS1421373-65-0

Min.Order / FOB Price:Get Latest Price

1 Gram	Negotiable

1 Gram

Negotiable

Min.Order :1 Gram
Purity: 99%
Payment Terms : L/C,T/T,

Keywords

AZD-9291 99%AZD-9291 AZD-9291

Quick Details

Appearance:white powder
Application:AZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 =
PackAge:As customer request
ProductionCapacity:100|Kilogram|Month
Storage:
Transportation:By Sea/Air/Courier

Superiority:

Triumph Chemical Title

Triumph Company Office picture

Triumph Company advantage

Triumph Testing title picture

Triumph Testing way

Welcome to contact us

Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.

Details:

AZD-9291

CAS:	1421373-65-0
MF:	C28H33N7O2
MW:	499.61
Appearance:	White powder
Assay:	99%
density:	1.19±0.1 g/cm3(Predicted)
Uses:	AZD-9291 (Osimertinib) is a oral, third generation, small-molecule epidermal growth factor receptor (EGFR) inhibitor and antineoplastic agent. In addition, it is a Cytochrome P450 3A inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor. It is used for the treatment of advanced non-small cell lung cancer (NSCLC) where mutant EGFR form (such as T790M) is often presented. Through suppressing the EGFR-mediated signalling, it cause cell death and inhibit tumour growth in related cancer cells.

View All

Visit Store